ArticleJMIR AI2023
Predicting Treatment Interruption Among People Living With HIV in Nigeria: Machine Learning Approach.
Article in JMIR AI, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Machine Learning in HIV Care and Antiretroviral Therapy: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Evaluating predictive performance, validity, and applicability of machine learning models for predicting HIV treatment interruption: a systematic review.BMC global and public health · 2025Pooled it
- Feasibility of AI-Enabled Chatbots for Pre-consultation in HIV Care in Northern Nigeria.International journal of behavioral medicine · 2026Article
- Prediction of First and Multiple Antiretroviral Therapy Interruptions in People Living With HIV: Comparative Survival Analysis Using Cox and Explainable Machine Learning Models.JMIR medical informatics · 2026Article
- Applying Machine Learning to Predict Loss to Follow-Up Among People Living With HIV in Haiti Using a National Electronic Medical Record Cohort.International journal of public health · 2026Article
- Artificial intelligence approaches to predicting treatment non-adherence in chronic diseases: a narrative review.Frontiers in digital health · 2026Review
- Indigenous Knowledge and Food-Based Coping Mechanisms for ART Side Effects: A Qualitative Inquiry.AIDS research and treatment · 2026Article
- Predicting antiretroviral therapy adherence status of adult HIV-positive patients using machine-learning Northwest, Ethiopia, 2025.BMC medical informatics and decision making · 2025Article
- Use of machine learning in predicting continuity of HIV treatment in selected Nigerian States.PLOS global public health · 2025Article
- Triaging Clients at Risk of Disengagement from HIV Care: Application of a Predictive Model to Clinical Trial Data in South Africa.Risk management and healthcare policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiretroviral therapy (ART) has transformed HIV from a fatal illness to a chronic disease. Given the high rate of treatment interruptions, HIV programs use a range of approaches to support individuals in adhering to ART and in re-engaging those who interrupt treatment. These interventions can often be time-consuming and costly, and thus providing for all may not be sustainable.
objectiveThis study aims to describe our experiences developing a machine learning (ML) model to predict interruption in treatment (IIT) at 30 days among people living with HIV newly enrolled on ART in Nigeria and our integration of the model into the routine information system. In addition, we collected health workers' perceptions and use of the model's outputs for case management.
methodsRoutine program data collected from January 2005 through February 2021 was used to train and test an ML model (boosting tree and Extreme Gradient Boosting) to predict future IIT. Data were randomly sampled using an 80/20 split into training and test data sets, respectively. Model performance was estimated using sensitivity, specificity, and positive and negative predictive values. Variables considered to be highly associated with treatment interruption were preselected by a group of HIV prevention researchers, program experts, and biostatisticians for inclusion in the model. Individuals were defined as having IIT if they were provided a 30-day supply of antiretrovirals but did not return for a refill within 28 days of their scheduled follow-up visit date. Outputs from the ML model were shared weekly with health care workers at selected facilities.
resultsAfter data cleaning, complete data for 136,747 clients were used for the analysis. The percentage of IIT cases decreased from 58.6% (36,663/61,864) before 2017 to 14.2% (3690/28,046) from October 2019 through February 2021. Overall IIT was higher among clients who were sicker at enrollment. Other factors that were significantly associated with IIT included pregnancy and breastfeeding status and facility characteristics (location, service level, and service type). Several models were initially developed; the selected model had a sensitivity of 81%, specificity of 88%, positive predictive value of 83%, and negative predictive value of 87%, and was successfully integrated into the national electronic medical records database. During field-testing, the majority of users reported that an IIT prediction tool could lead to proactive steps for preventing IIT and improving patient outcomes.
conclusionsHigh-performing ML models to identify patients with HIV at risk of IIT can be developed using routinely collected service delivery data and integrated into routine health management information systems. Machine learning can improve the targeting of interventions through differentiated models of care before patients interrupt treatment, resulting in increased cost-effectiveness and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.